XX XXXX XXXXX XXXX XXX

Associate Professor and

Consultant Medical Oncologist

University College London

72 Huntley Street

London, WC1E 6BT

Tel: 0203 447 9088

6th August 2021

Dear Mr Irish,

**Re: Appeal against NICE FAD Avelumab for maintenance treatment of localy advanced or metastatic urothelial cancer after platinum based chemotherapy (ID3735)**

I am a Medical Oncologist and member of the Association of Cancer Physicians (ACP). With the support of XXXX XXXXX XXXXXXXXXX, Chair of the ACP, I am writing personally and on behalf of the ACP members that treat urothelial cancer (including XXXX XXX XXXXXX, XX XXXXX XXXXX, XXXX XXX XXXXX and XXXX XXXX XXXXXXX). We strongly believe that there are several aspects of the FAD that are incorrect:

**NICE has failed to act fairly and not listened to clinical experts**

A 2 year stopping rule was suggested to NICE but rejected on the basis that this would be difficult for clinicians to impose and that this was not what was done in the trial. We already have a precedent of NICE imposed 2 year stopping rules for 2nd line atezolizumab in advanced urothelial cancer and clinicians we are able to enforce this without problems.

While the median survival in the control arm was 14.3 months NICE estimated the mean survival as over 24 months and therefore did not meet EoL criteria. This is not in keeping with UK clinicians’ experience. The UK based LAMB study in 446 patients in this comparable group had a overall survival of 12.0 months in the control arm. This was performed in pre-immunotherapy era so I have looked at my cohort of patients at UCLH treated since the advent of immunotherapy. In our UK patient group (n=64) the median survival is 14 months.

I hope that you reconsider this outcome for the benefit or our patients with urothelial cancer in the UK. I wish this to be heard as part of a written appeal.

Kind regards

XX XXXX XXXXX

Consultant Oncologist